PepGen Reports 46.5% Splicing Correction in DM1 Trial
PepGen's 10 mg/kg cohort achieved 46.5% mean splicing correction. Results from the fully enrolled 12.5 mg/kg cohort are due in 2027, while $104.8 million supports operations into 2028.
Topic
Clinical Trials
Topic
Clinical Trials
SeaX Ventures Links US Heart-Patch Startup Skribe to SE Asia Clinics
SeaX Ventures recruited 100+ Southeast Asian patients for Skribe Medical's heart-monitor patch studies, after leading the startup…
VectorY Raises €74.5 Million to Push ALS Antibody Into Late Readout
VectorY Therapeutics raised €74.5 million from new and returning investors to fund the final PIONEER-ALS readout for VTx-002 and…
Retatrutide Cut Knee Pain by Half in 63% to 70% of Patients
Northwestern University's Eli Lilly-funded phase 3 trials found 63% to 70% of participants on higher retatrutide doses halved kne…
Phio Pharmaceuticals' Q3 Net Loss Widens to $4.2M on PH-762 Push
Phio Pharmaceuticals' Q3 2026 net loss widened to $4.2 million as R&D spending jumped 159%, with cash halving to $10.6 million ah…
Foundayo cut sleep apnea events by 21.1 an hour in late-stage trial
Eli Lilly’s Foundayo cut apnea events by 21.1 per hour at 52 weeks in a late-stage trial; Lilly plans a year-end U.S. filing for…
Biograil Raises €20 Million to Push Oral Biologic Delivery Into Clinics
Copenhagen's Biograil raises €20 million from Verve Ventures, Megatrend Invest and HTGF to advance its capsule-based BIONDD® oral…
Specific Biologics raises $35 million for ALS gene editing
Specific Biologics raised $35 million to move a C9ORF72-linked ALS gene-editing candidate into an adaptive Phase I/II trial, back…
Biograil closes €20 million to replace injections with swallowable drug device
Copenhagen's Biograil raised €20 million from Verve Ventures, Megatrend Invest and HTGF to advance its swallowable BIONDD device…
Flow Medical closes $6 million round for HELYX-PE system
Flow Medical closed a $6 million financing for HELYX-PE, a catheter-based pulmonary embolism system headed toward first-in-human…
Windward Bio seeks Nasdaq listing after raising $365 million
Basel-based Windward Bio filed to list on Nasdaq after raising up to $365.0 million. WIN378 data support twice-yearly dosing, whi…